[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5550466A2 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
CO5550466A2
CO5550466A2 CO03110716A CO03110716A CO5550466A2 CO 5550466 A2 CO5550466 A2 CO 5550466A2 CO 03110716 A CO03110716 A CO 03110716A CO 03110716 A CO03110716 A CO 03110716A CO 5550466 A2 CO5550466 A2 CO 5550466A2
Authority
CO
Colombia
Prior art keywords
oxa
diazabicyclo
butyl
formulation
ethylcarbamate
Prior art date
Application number
CO03110716A
Other languages
English (en)
Inventor
Khoo Cynthia Gaik-Lim
Helena Gustafsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5550466A2 publication Critical patent/CO5550466A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una formulación farmacéutica oral que comprende iota carragenina, uno o más polímeros gelatinizantes neutros y un ingrediente básico farmacéuticamente activo; formulación que inhibe la liberación del ingrediente básico farmacéuticamente activo de la formulación con pH ácido.4.- Una formulación como se reivindica en reivindicación 1 en donde el ingrediente básico farmacéuticamente activo es:4-({3-[7-(3,3-dimetil-2-oxobutil)-9-oxa-3,7-diazabiciclo[3.3.1]non-3-il]propil}amino)benzonitrilo;tert-butil 2-(7-[3-(4-cianoanilino)propil]-9-oxa-3,7-diazabiciclo-[3.3.1]non-3-il}etilcarbamato;tert-butil 2-{7-[4-(4-cianofenil)butil]-9-oxa-3,7 -diazabiciclo-[3.3.1]non-3-il} etilcarbamato; otert-butil 2- {7-[(2S)-3-(4-cianofenoxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo[3.3.1]non-3-il}etilcarbamato.
CO03110716A 2001-06-21 2003-12-18 Formulacion farmaceutica CO5550466A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CO5550466A2 true CO5550466A2 (es) 2005-08-31

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03110716A CO5550466A2 (es) 2001-06-21 2003-12-18 Formulacion farmaceutica

Country Status (31)

Country Link
US (1) US7700582B2 (es)
EP (1) EP1401502B1 (es)
JP (1) JP2005501024A (es)
KR (1) KR20040011542A (es)
CN (1) CN1518462A (es)
AR (1) AR034517A1 (es)
AT (1) ATE314093T1 (es)
AU (1) AU2002345463B2 (es)
BG (1) BG108516A (es)
BR (1) BR0210489A (es)
CA (1) CA2450449A1 (es)
CO (1) CO5550466A2 (es)
CZ (1) CZ299859B6 (es)
DE (1) DE60208369T2 (es)
DK (1) DK1401502T3 (es)
EE (1) EE200400028A (es)
ES (1) ES2254699T3 (es)
HU (1) HUP0400850A3 (es)
IL (2) IL159217A0 (es)
IS (1) IS2347B (es)
MX (1) MXPA03011546A (es)
MY (1) MY130332A (es)
NO (1) NO20035627D0 (es)
NZ (1) NZ530086A (es)
PL (1) PL366432A1 (es)
RU (1) RU2323006C2 (es)
SI (1) SI1401502T1 (es)
SK (1) SK286238B6 (es)
UA (1) UA77959C2 (es)
WO (1) WO2003000293A1 (es)
ZA (1) ZA200309316B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
JP4882200B2 (ja) * 2001-11-13 2012-02-22 アステラス製薬株式会社 水溶性薬物徐放化技術
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2584469A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TWI453041B (zh) * 2007-02-01 2014-09-21 Takeda Pharmaceutical 固體型製劑
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
ATE159030T1 (de) 1992-03-04 1997-10-15 Gyogyszerkutato Intezet Neuartige antikoagulierende peptidderivate und arzneimittel die solche enthalten so wie entsprechendes herstellungsverfahren
TW223629B (es) 1992-03-06 1994-05-11 Hoffmann La Roche
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
EA199700186A1 (ru) * 1995-02-17 1998-02-26 Басф Акциенгезельшафт Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
CA2258915A1 (en) 1996-06-25 1997-12-31 Michael Robert Wiley Anticoagulant agents
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IL141688A0 (en) * 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
ES2295004T3 (es) * 1999-01-13 2008-04-16 Astrazeneca Ab Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina.
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
US20040242536A1 (en) 2004-12-02
DE60208369T2 (de) 2006-08-24
DK1401502T3 (da) 2006-04-10
MXPA03011546A (es) 2004-03-19
IS7081A (is) 2003-12-16
HUP0400850A2 (hu) 2004-08-30
RU2323006C2 (ru) 2008-04-27
ZA200309316B (en) 2005-02-28
BR0210489A (pt) 2004-06-22
AU2002345463B2 (en) 2007-08-30
ES2254699T3 (es) 2006-06-16
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
MY130332A (en) 2007-06-29
NZ530086A (en) 2005-09-30
CZ299859B6 (cs) 2008-12-17
ATE314093T1 (de) 2006-01-15
IL159217A0 (en) 2004-06-01
EE200400028A (et) 2004-04-15
EP1401502A1 (en) 2004-03-31
CA2450449A1 (en) 2003-01-03
IL159217A (en) 2009-02-11
CN1518462A (zh) 2004-08-04
AR034517A1 (es) 2004-02-25
NO20035627D0 (no) 2003-12-15
SK286238B6 (sk) 2008-06-06
RU2003136155A (ru) 2005-05-20
CZ20033491A3 (en) 2004-03-17
SI1401502T1 (sl) 2006-06-30
IS2347B (is) 2008-03-15
BG108516A (en) 2004-12-30
DE60208369D1 (de) 2006-02-02
WO2003000293A1 (en) 2003-01-03
HUP0400850A3 (en) 2010-10-28
UA77959C2 (en) 2007-02-15
JP2005501024A (ja) 2005-01-13
EP1401502B1 (en) 2005-12-28
SK15912003A3 (sk) 2004-05-04
US7700582B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
CO5550466A2 (es) Formulacion farmaceutica
HRP20191665T1 (hr) Sastavi pirolopirola kao aktivatori piruvat kinaze (pkr)
DK1372608T3 (da) Medicinske aerosolformuleringer
SV2002000248A (es) Composicion farmaceutica suministrando concentracion aumentada de la droga ref. pc10755ajtj/bb
RS50814B (sr) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
EA201001086A1 (ru) Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
ATE227597T1 (de) Implantat
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
NO2014006I2 (no) Vemurafenib. Propan-l-sulfonsyre{3-[5-(4-klorfenyl)-lH-pyrrolo[2,3-b]pyridin-3-karbonyl]-2,4-difluor-fenyl}-amid
DE59904648D1 (de) Medizinische aerosolformulierungen
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
AR035452A1 (es) Sales farmaceuticamente aceptables de compuestos antiarritmicos, procedimiento para la preparación de estas sales, formulación farmaceutica y el uso de estos compuestos para la manufactura de medicamentos para el uso en la profilaxis o el tratamiento de una arritmia
ATE447397T1 (de) Darreichungsform mit erhöhter bioverfügbarkeit
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
UA102271C2 (en) Solid pharmaceutical composition (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazole -3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate
NO20073023L (no) Forhindring av vertikal endoparasitt infeksjoner
AR030756A1 (es) Compuesto de oxabispidina util en el tratamiento de arritmias cardiacas
AR035806A1 (es) Formulacion farmaceutica de liberacion inmediata apropiada para compuestos antiarritmicos, procedimiento para su preparacion, composicion farmaceutica solida, composicion liofilizada, uso de la formulacion o la composicion para la manufactura de un medicamento para ser usado en la profilaxis o trata
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
MY141595A (en) New modified release formulation suitable for antiarrhythmic compounds
SE0000303D0 (sv) Novel compounds
BR0008442A (pt) Formulação efervescente farmacêutica, contendo metamizol

Legal Events

Date Code Title Description
FC Application refused